Key elements of the consensus are (1) allo-SCT is a procedure with evidence-based efficacy in poor-risk CLL; (2) although definition of 'poor-risk CLL' requires further investigation, allo-SCT is a reasonable treatment option for younger patients with (i) non-response or early relapse (within 12 months) after purine ...
Nov 16, 2006 · The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred ...
Aug 25, 2020 · was recommended for patients with poor-risk chronic lymphocytic leukemia (CLL), specifically those with early relapse or refractory disease ...
Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL)
People also ask
What are the indications for stem cell transplant?
Who is eligible for allogeneic stem cell transplant?
Who is a candidate for allogeneic stem cell transplant?
What is the main reason for using an allogeneic stem cell transplant?
The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option ...
Indications for allogeneic stem cell transplantation in chronic ...
db.cngb.org › search › literature
The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option ...
guidelines recommend allogeneic HCT for eligible patients with relapsed standard-risk CLL who develop BTK inhibitor resistance, and for high-risk patients with ...
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. February 2007; Leukemia 21(1):12-7. 21(1): ...
Clinical Practice Recommendations for Use of Allogeneic ...
www.astctjournal.org › article › fulltext
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007; 21:12-17. Crossref · Scopus ...
May 19, 2022 · This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders.